Summary
Research interests
The team's work aims to elucidate the complex role of poly(ADP-ribosyl)ation reactions in the mechanisms that control genome stability, tumorigenesis and cell differentiation processes. Our previous work focused on the enzymes that synthesize poly(ADP-ribose) (PAR) in response to damage, the poly(ADP-ribose) polymerases PARP1 and PARP2, and the one that degrades it, the poly(ADP-ribose) glycohydrolase (PARG).
We have shown that PARP1 is a molecular sensor of DNA breaks and plays a key role in the spatial and temporal organization of their repair. Its inhibition is now used as an effective therapeutic strategy to potentiate the cytotoxic action of chemo- or radiotherapy or to target cancers deficient in DNA repair mechanisms (BRCA1mut cancers). PARP2 is also involved in the maintenance of genome integrity. Biochemical studies as well as animal and cellular models deficient in PARP1 or PARP2 developed in the laboratory have revealed the redundant aspects of these two enzymes in the surveillance of genome integrity, but also specific functions in the regulation of transcription, chromatin organization and cell differentiation. We have highlighted a crucial role of PARG in preventing the harmful accumulation of PAR after irradiation or during prolonged replicative stress.
In recent years, we have refocused our objectives on the biochemical and functional characterization of the 3rd member of this family, PARP3. We have identified its role in the repair of double-strand breaks, in tumor aggressiveness and in cell differentiation in physiological models. We are continuing these functional characterization studies, particularly in cancer, by combining complementary experimental approaches of biochemistry, molecular and cellular biology as well as by the development and phenotypic characterization of cellular models (with particular attention to stem cells) and loss-of-function animal models (Crispr/Cas9, knockout mice). Finally, from a more translational perspective, we are developing new tools targeting PARP3 (screening of chemical libraries, antibody-drug conjugates) for therapeutic purposes.
Contact
Dr Françoise Dantzer
Funding
Team members
- Bureau : D405
- jean-christophe.ame[at]unistra.fr
- Bureau : D403
- khouloud.chtiba2[at]etu.unistra.fr
- Bureau : D415
- agnes.cordonnier[at]unistra.fr
- Bureau : D407
- Bureau : D404
- francoise.dantzer[at]unistra.fr
- Bureau : D405
- najat.hanini[at]unistra.fr
- Bureau : D406
- aurelia.noll[at]unistra.fr
- Bureau : D405
- rodriguezcandela[at]unistra.fr
- Bureau : D407
- zeniou[at]unistra.fr
Publications
Varol A, Klauck SM, Dantzer F, Efferth T (2024). Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer. Chem Biol Interact 398:111094. doi: 10.1016/j.cbi.2024.111094.
Bencsics M, Bányai B, Ke H, Csépányi-Kömi R, Sasvári P, Dantzer F, Hanini N, Benkő R, Horváth EM (2023). PARP2 downregulation in T cells ameliorates lipopolysaccharide-induced inflammation of the large intestine. Front Immunol 14:1135410. doi: 10.3389/fimmu.2023.1135410.
Amé JC, Nguekeu-Zebase L, Harwood D, Yildirim Z, Roegel L, Boos A, Dantzer F (2023). Purification of Recombinant Human PARP-3. Methods Mol Biol 2609:419-441. doi: 10.1007/978-1-0716-2891-1_26.
Amé JC, Dantzer F (2023). Purification of Recombinant Human PARG and Activity Assays. Methods Mol Biol 2609:399-418. doi: 10.1007/978-1-0716-2891-1_25.
Nguekeu-Zebaze L, Hanini N, Noll A, Wadier N, Amé JC, Roegel L, Dantzer F (2022). PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells. Scientific Reports 12:15534. doi: 10.1038/s41598-022-19525-6.
Galindo-Campos MA, Lutfi N, Bonnin S, Martínez C, Velasco-Hernandez T, García-Hernández V, Martin-Caballero J, Ampurdanés C, Gimeno R, Colomo L, Roue G, Guilbaud G, Dantzer F, Navarro P, Murga M, Fernandez-Capetillo O, Bigas A, Menendez P, Sale J, Yélamos J (2022). Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cella lymphoma in mice. Blood 139:228-239. doi: 10.1182/blood.2021012805.
Lüscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, Cohen M, Corda D, Dantzer F, Daugherty MD, Dawson TM, Dawson VL, Deindl S, Fehr AR, Feijs KLH, Filippov DV, Gagné JP, Grimaldi G, Guettler S, Hoch NC, Hottiger MO, Korn P, Kraus WL, Ladurner A, Lehtiö L, Leung AKL, Lord CJ, Mangerich A, Matic I, Matthews J, Moldovan GL, Moss J, Natoli G, Nielsen ML, Niepel M, Nolte F, Pascal J, Paschal BM, Pawlowski K, Poirier GG, Smith S, Timinszky G, Wang ZQ, Yélamos J, Yu X, Zaja R, Ziegler M (2021). ADP-ribosyltransferases, an update on function and nomenclature. FEBS J 289(23):7399-7410. doi: 10.1111/febs.16142.
Kelleher AM, Setlem R, Dantzer F, deMayo FJ, Lydon JP, Kraus WL (2021). Deficiency of PARP-1 and PARP-2 in the mouse uterus results in decidualization failure and pregnancy loss. Proc Natl Acad Sci USA 118:e2109252118. doi: 10.1073/pnas.2109252118.
Martí JM, Garcia-Diaz A, Delgado-Bellido D, O'Valle F, González-Flores A, Carlevaris O, Rodríguez-Vargas JM, Amé JC, Dantzer F, King GL, Dziedzic K, Berra E, de Álava E, Amaral AT, Hammond EM, Oliver FJ (2021). Selective modulation by PARP-1 of HIF-1a-recruitement to chromatin during hypoxia is required for tumor adaptatiion to hypoxic conditions. Redox Biol 41:101885. doi: 10.1016/j.redox.2021.101885.
Rodriguez-Vargas JM, Martin-Hernandez K, Wang W, Kunath N, Suganthan R, Amé JC, Oliver FJ, Ye J, Bjørås M, Dantzer F (2020). Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induved ROS and mTorc2 activation. Cell Death Dis 11:954. doi: 10.1038/s41419-020-03167-5.
Moreno-Lama L, Galindo-Campos MA, Martínez C, Comerma L, Vazquez I, Vernet-Tomas M, Ampurdanés C, Lutfi N, Martin-Caballero J, Dantzer F, Quintela-Fandino M, Ali SO, Jimeno J, Yélamos J (2020). Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene 39:2835-2843. doi: 10.1038/s41388-020-1175-x.
Lambert S, Borde V, Charbonnier JB, Dantzer F, Espéli O, Guirouilh-Barbat J, Llorente B, Legube G, Prioleau MN, Radicella P (2020). Des mécanismes moléculaires aux applications cliniques. L’essentiel du Colloque Réplication-Réparation-Recombinaison 2019. Bull Cancer 107:283-287. doi: 10.1016/j.bulcan.2020.01.003.
Rodríguez-Vargas JM, Oliver-Pozo FJ, Dantzer F (2019). PARP1 and Poly(ADP-ribosyl)ation Signaling during Autophagy in Response to Nutrient Deprivation. Oxid Med Cell Longev 2019:2641712. doi: 10.1155/2019/2641712.
Zeniou M, Nguekeu-Zebaze L, Dantzer F (2019). Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond. Biochem Pharmacol 167:107-115. doi: 10.1016/j.bcp.2019.06.012.
Galindo-Campos MA, Bedora-Faure M, Farrés J, Lescale C, Moreno-Lama L, Martínez C, Martín-Caballero J, Ampurdanés C, Aparicio P, Dantzer F, Cerutti A, Deriano L, Yélamos J (2019). Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function. Cell Death Differ 26:2667-2681. doi: 10.1038/s41418-019-0326-5.
Rodriguez-Vargas JM, Nguekeu-Zebaze L, Dantzer F (2019). PARP3 comes to light as a prime target in cancer therapy. Cell Cycle 18:1295-1301. doi: 10.1080/15384101.2019.1617454.
Beck C, Rodriguez-Vargas JM, Boehler C, Robert I, Heyer V, Hanini N, Gauthier LR, Tissier A, Schreiber V, Elofsson M, Reina San Martin B, Dantzer F (2019). PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers. Cell Death Differ 26:1615-1630. doi: 10.1038/s41418-018-0233-1.
Chen Q, Kassab MA, Dantzer F, Yu X (2018). PARP2 mediates branched poly ADP-ribosylation in response to DNA damage. Nat Commun 9:3233. doi: 10.1038/s41467-018-05588-5.
Dörsam B, Seiwert N, Foersch S, Stroh S, Nagel G, Begaliew D, Diehl E, Kraus A, McKeague M, Minneker V, Roukos V, Reißig S, Waisman A, Moehler M, Stier A, Mangerich A, Dantzer F, Kaina B, Fahrer J (2018). PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A 115:E4061-E4070. doi: 10.1073/pnas.1712345115.
Filliol A, Piquet-Pellorce C, Dion S, Genet V, Lucas-Clerc C, Dantzer F, Samson M (2017). PARP2 deficiency affects invariant-NKT-cell maturation and protects mice from Concanavalin A-induced liver injury. Am J Physiol Gastrointest Liver Physiol 313:G399-G409. doi: 10.1152/ajpgi.00436.2016.
Robert I, Gaudot L, Yelamos J, Noll A, Wong HK, Dantzer F, Schreiber V, Reina-San-Martin B (2017). Robust immunoglobulin class switch recombination and end-joining in Parp9-deficient mice. Eur J Immunol 47:665-676. doi: 10.1002/eji.201646757.
Amé JC, Camuzeaux B, Dantzer F, Schreiber V (2017). Purification of Recombinant human PARP-3. Methods Mol Biol 1608:373-394. doi: 10.1007/978-1-4939-6993-7_24.
Amé JC, Héberlé E, Camuzeaux B, Dantzer F, Schreiber V (2017). Purification of Recombinant Human PARG and Activity Assays. Methods Mol Biol 1608:395-413. doi: 10.1007/978-1-4939-6993-7_25.
Navarro J, Gozalbo-López B, Méndez A, Dantzer F, Schreiber V, Martínez CM, Arana D, Farrés J, Revilla-Nuin B, Bueno M, Ampurdanés C, Galindo-Campos M, Knobel P, Segura-Bayona S, Martín-Caballero J, Stracker T, Aparicio P, Del Val M, Yelamos J (2017). PARP-1/PARP-2 double deficiency in mouse T-cells results in faulty immune responses and T lymphomas. Sci Rep 7:41962. doi: 10.1038/srep41962.
Martin-Hernandez K, Rodriguez-Vargas JM, Schreiber V, Dantzer F (2017). Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Semin Cell Dev Biol 63:92-101. doi: 10.1016/j.semcdb.2016.09.009.
Noll A, Illuzzi G, Amé J-C, Dantzer F, Schreiber V (2016). PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deciency. Cancer Cell Int 16:53.
Karicheva O, Rodriguez-Vargas JM, Wadier N, Martin-Hernandez K, Vauchelles R, Magroun N, Tissier A, Schreiber V, Dantzer F (2016). PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget 7:64109-64123.
Becker A, Zhang P, Allmann L, Meilinger D, Bertulat B, Eck D, Hofstaetter M, Bartolomei G, Hottiger MO, Schreiber V, Leonhardt H, Cardoso MC (2016). Poly(ADP-ribosyl)ation of methyl CpG binding protein 2 regulates chromatin structure. J Biol Chem 291:4873-81.
Soret C, Martin E, Duluc I, Dantzer F, Vanier M, Gross I, Freund JN, Domon-Dell C (2016). Distinct mechanisms for opposite functions of homeoproteins Cdx2 and HoxB7 in double-strand break DNA repair in colon cancer cells. Cancer Lett 374:208-15.
Visochek L, Grigoryan G, Kalal A, Milshtein-Parush H, Gazit N, Slutsky I, Yeheskel A, Shainberg A, Castiel A, Seger R, Langelier MF, Dantzer F, Pascal JM, Segal M, Cohen-Armon M (2016). A PARP1-ERK2 synergism is required for the induction of LTP. Sci Rep 6:24950.
Ghosh R, Roy S, Kamyab J, Dantzer F, Franco S (2016). Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways. DNA Repair 45:56-62.
Rodríguez-Vargas JM, Rodríguez MI, Majuelos-Melguizo J, García-Diaz Á, González-Flores A, López-Rivas A, Virág L, Illuzzi G, Schreiber V, Dantzer F, Oliver FJ (2016). Autophagy requires poly(adp-ribosyl)ation-dependent AMPK nuclear export. Cell Death Differ 23:2007-2018.
Farrés J, Lacune L, Martin-Caballero J, Martínez C, Lozano JJ, Ampurdanés C, López-Contreras AJ, Florensa L, Navarro J, Ottina E, Dantzer F, Schreiber V, Villunger A, Fernández-Capetillo O, Yélamos J (2015). PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ 22:1144-1157.
Kutuzov MM, Khodyreva SN, Ilina ES, Sukhanova MV, Amé JC, Lavrik OI (2015). Interaction of PARP-2 with AP site containing DNA. Biochimie 112:10-9.
Robert I, Gaudot L, Rogier M, Heyer V, Noll A, Dantzer F, Reina-San-Martin B (2015). Parp3 negatively regulates immunoglobulin class switch recombination. PLoS Genet 11:e1005240.
Schreiber V, Illuzzi G, Héberlé E, Dantzer F (2015). From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy. Bull Cancer 102:863–873.
Illuzzi G, Fouquerel E, Amé JC, Noll A, Rehmet K, Nasheuer HP, Dantzer F, Schreiber V (2014). PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress. Nucleic Acids Res 15:18-25.
De Vos M, El Ramy R, Quénet D, Wolf P, Spada F, Magroun N, Babbio F, Schreiber V, Leonhardt H, Bonapace IM, Dantzer F (2014). Poly(ADP-ribose) polymerase 1 (PARP1) associates with E3 ubiquitin-protein ligase UHRF1 and modulates UHRF1 biological functions. J Biol Chem 289:16223-38.
Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F (2014). Poly(ADP-ribose) polymerases in double-strand break repair : Focus on PARP1, PARP2 and PARP3. Exp Cell Res 15:18-25.
Beck C, Boehler C, Guirouilh Barbat J, Bonnet ME, Illuzzi G, Ronde P, Gauthier LR, Magroun N, Rajendran A, Lopez BS, Scully R, Boussin FD, Schreiber V, Dantzer F (2014). PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Res 42:5616-5632.
Kutuzov MM, Khodyreva SN, Schreiber V, Lavrik OI (2014). The role of PARP2 in DNA repair. Mol Biol (Mosk) 48:561-72.
Das BB, Huang SY, Murai J, Rehman I, Ame JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, Majumder HK, Schreiber V, Pommier Y (2014). PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 42:4435-4449.
Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, Zeviani M (2014). NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042-1049.
Robert I, Karicheva O, Reina San Martin B, Schreiber V, Dantzer F (2013). Functional aspects of PARylation in induced and programmed DNA repair processes : Preserving genome integrity and modulating physiological events. Mol Aspects Med 34:1138-1152.
Dantzer F, Santoro R (2013). The expanding role of PARPs in the establishment and maintenance of heterochromatin. FEBS J 280:3508-3518.
Castiel A, Visochek L, Mittelman L, Zilberstein Y, Dantzer F, Izraeli S, Cohen-Armon M (2013). Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells. J Vis Exp 78:e50568.
Legrand AJ, Choul-Li S, Spriet C, Idziorek T, Vicogne D, Drobecq H, Dantzer F, Villeret V, Aumercier M (2013). The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage. PLoS One 8:e55883.
Kutuzov MM, Khodyreva SN, Amé JC, Ilina ES, Sukhanova MV, Schreiber V, Lavrik OI (2013). Interaction of PARP-2 with DNA structures mimicking DNA repair intermediates and consequences on activity of base excision repair proteins. Biochimie 95:1208-1215.
Farrés J, Martín-Caballero J, Martínez C, Lozano JJ, Llacuna L, Ampurdanés C, Ruiz-Herguido C, Dantzer F, Schreiber V, Villunger A, Bigas A, Yélamos J (2013). Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood 122:44-54.
Le May N, Iltis I, Amé JC, Zhovmer A, Biard D, Egly JM, Schreiber V, Coin F (2012). Poly (ADP-ribose) glycohydrolase regulates retinoic acid receptor-mediated gene expression. Mol Cell 48:785-798.
De Vos M, Schreiber V, Dantzer F (2012). The diverse roles and clinical relevance of PARPs in DNA damage repair : current state of the art. Biochem Pharmacol 84:137-146.
Kalisch T, Amé JC, Dantzer F, Schreiber V (2012). New readers and interpretations of poly(ADP-ribosyl)ation. Trends Biochem Sci 37:381-390.
Anjos SM, Robert R, Waller D, Zhang DL, Balghi H, Sampson HM, Ciciriello F, Lesimple P, Carlile GW, Goepp J, Liao J, Ferraro P, Phillipe R, Dantzer F, Hanrahan JW, Thomas DY (2012). Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking. Front Pharmacol 3:165.
Dantzer F, Noël G, Schreiber V (2011). PARP inhibitors : significant progress in cancer therapy. Bull Cancer 98:277-290.
Boehler C, Gauthier LR, Mortusewicz O, Biard D, Saliou JM, Bresson A, Sanglier-Cianferani S, Smith S, Schreiber V, Boussin FD, Dantzer F (2011). PARP3, a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA 108:2783-2788.
Boehler C, Gauthier LR, Yelamos J, Noll A, Schreiber V, Dantzer F (2011). Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells. Methods Mol Biol780:313-36.
Boehler C, Dantzer F (2011). PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression. Cell Cycle 10:1023–1024.
Mortusewicz O, Fouquerel E, Amé JC, Leonhardt H, Schreiber V (2011). PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms. Nucleic Acids Res 39:5045-5056.
Amé JC, Kalisch T, Dantzer F, Schreiber V (2011). Purification of recombinant poly(ADP-ribose) polymerases. Methods Mol Biol 780:135-152.
Castiel A, Visochek L, Mittelman L, Dantzer F, Izraeli S, Cohen-Armon M (2011). A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer 11:412.
Rodriguez MI, Gonzalez-Flores A, Dantzer F, Collard J, de Herreros AG, Oliver FJ (2011). Poly(ADP-ribose)-dependent regulation of Snail1 protein stability. Oncogene 30:4365-4372.
Bai P, Cantó C, Brunyánszki A, Huber A, Szántó M, Cen Y, Yamamoto H, Houten SM, Kiss B, Oudart H, Gergely P, Ménissier-de Murcia J, Schreiber V, Sauve AA, Auwerx J (2011). PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 13:450-460.
Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, Schoonjans K, Schreiber V, Sauve AA, Ménissier-de Murcia J, Auwerx J (2011). PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 13:461-468.
Brunyánszki A, Hegedus C, Szántó M, Erdélyi K, Kovács K, Schreiber V, Gergely S, Kiss B, Szabó E, Virág L, Bai P (2010). Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress. J Invest Dermatol 130:2629-37.
Nicolas L, Martinez C, Baro C, Rodriguez M, Baroja-Mazo A, Sole F, Flores J, Ampurdanes C, Dantzer F, Martin-Cabarello J, Aparicio P, Yelamos J (2010). Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T cell lymphomas in p53 deficient mice. Oncogene 29:2877–2883.
Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G (2010). Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. Curr Cancer Drug Targets 10:368-83.
Ambrose HE, Willimott S, Beswick RW, Dantzer F, de Murcia JM, Yelamos J, Wagner SD (2009). Poly(ADP-ribose) polymerase-1 (Parp-1)-deficient mice demonstrate abnormal antibody responses. Immunology 127:178-86.
Amé JC, Fouquerel E, Gauthier LR, Biard B, Boussin FD, Dantzer F, de Murcia G, Schreiber V (2009). Radiation-induced mitotic catastrophe in PARG-deficient cells. J Cell Sci 122:1990-2002.
Amé JC, Hakmé A, Quénet D, Fouquerel E, Dantzer F, Schreiber V (2009). Detection of the nuclear poly(ADP-ribose)-metabolizing enzymes and activities inresponse to DNA damage. Methods Mol Biol 464:267-83.
El Ramy R, Magroun N, Messadecq N, Gauthier LR, Boussin FD, Kolthur-Seetharam U, Schreiber V, McBurney MW, Sassone-Corsi P, Dantzer F (2009). Functional interplay between Parp-1 and SirT1 in genome integrity and chromatin-based processes. Cell Mol Life Sci 66:3219-34.
Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, Cohen-Armon M (2009). A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 11:R78.
Kotoglou P, Kalaitzakis A, Vezyraki P, Tzavaras T, Michalis LK, Dantzer F, Jung JU, Angelidis C (2009). Hsp70 translocates to the nuclei and nucleoli, binds to XRCC1 and PARP-1, and protects HeLa cells from single-strand DNA breaks. Cell Stress Chaperones 14:391-406.
Lévy N, Oehlmann M, Delalande F, Nasheuer HP, Van Dorsselaer A, Schreiber V, de Murcia G, Ménissier-de Murcia J, Maiorano D, Bresson A (2009). XRCC1 interacts with the p58 subunit of DNA Pol alpha-primase and may coordinate DNA repair and replication during S phase. Nucleic Acids Res 37:3177-88.
Martin N, Schwamborn K, Schreiber V, Werner A, Sabatier L, Bischof O, Matunis M, Seeler J, Dejean A (2009). PARP-1 transcriptional activity is regulated by sumoylation upon heat shock. EMBO J 28:3534-48.
Nossa CW, Jain P, Tamilselvam B, Gupta VR, Chen LF, Schreiber V, Desnoyers S, Blanke SR (2009). Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori. Proc Natl Acad Sci USA 106:19998-20003.
Quénet D, El Ramy R, Schreiber V, Dantzer F (2009). The role of poly(ADP-ribosyl)ation in epigenetic events. Int J Biochem Cell Biol 41:60-5.
Quénet D, Mark M, Govin J, van Dorsselear A, Schreiber V, Khochbin S, Dantzer F (2009). Parp2 is required for the differentiation of post-meiotic germ cells : Identification of a spermatid-specific complex containing Parp1, Parp2, TP2 and HSPA2. Exp Cell Res 315:2824-34.
Robert I, Dantzer F, Reina-San-Martin B (2009). Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J Exp Med206:1047-56.
Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C (2009). A nuclear poly(ADP-ribose) - dependent signalosome confers DNA damage induced IkB kinase activation. Mol Cell 13:365-78.
Hakmé A, Huber A, Dollé P, Schreiber V (2008). The macroPARP genes Parp-9 and Parp-14 are developmentally and differentially regulated in mouse tissues. Dev Dyn 237:209-15.
Hakmé A, Wong HK, Dantzer F, Schreiber V (2008). The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep 9:1094-100.
Quénet D, Gasser V, Fouillen L, Cammas F, Sanglier-Cianferani S, Losson R, Dantzer F (2008). The histone subcode : poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1-beta and the heterochromatin protein HP1-alpha. FASEB J 22:3853-65.
Valdor R, Schreiber V, Saenz L, Martínez T, Muñoz-Suano A, Dominguez-Villar M, Ramírez P, Parrilla P, Aguado E, García-Cózar F, Yelamos J (2008). Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol Immunol 45:1863-71.
Yelamos J., Schreiber V., Dantzer F (2008). Towards specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 14:169-78.
Bai P, Houten SM, Huber A, Schreiber V, Watanabe M, Kiss B, de Murcia G, Auwerx J, Ménissier-de Murcia J (2007). PARP-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the RXR/PPARgamma heterodimer. J Biol Chem 282:37738-46.
Mortusewicz O, Amé JC, Schreiber V, Leonhardt H (2007). Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 5:7665-75.
Dantzer F, Mark M, Quenet D, Scherthan H, Huber A, Liebe B, Monaco L, Chicheportiche A, Sassone-Corsi P, de Murcia G, Ménissier-de Murcia J (2006). Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis. Proc Natl Acad Sci U S A 103:14854-9.